Navigation Links
S1 Biopharma Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
Date:6/5/2015

NEW YORK, June 5, 2015 /PRNewswire/ -- Yesterday's FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women's health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.  We are especially pleased for S1 Biopharma's Dr. Robert Pyke who fathered flibanserin at Boehringer Ingelheim before it was acquired by Sprout Pharmaceuticals.  Dr. Pyke joined S1 Biopharma as Chief Medical Officer in 2012 to develop our next-generation drug for HSDD, Lorexys.

HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity that cannot be accounted for by another medical, physical, or psychiatric condition, or medication.  An estimated 1 in 10 women may have HSDD at some point in their life, for which therapies like flibanserin with a 9%- 13% responder rate over placebo, and S1 Biopharma's first in class, next-generation drug Lorexys have been developed to address.

S1 Biopharma is currently preparing for upcoming Phase IIb studies for Lorexys for the treatment of HSDD.  In its recently completed Phase IIa study, Lorexys demonstrated a 76% responder rate that was 38% greater than control.

About S1 Biopharma

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's pipeline of therapies is non-hormonal, acting on the sexual centers of the brain by restoring the natural balance of key neurotransmitters. S1 Biopharma's pipeline utilizes its trademark philosophy of identifying and combining mechanistically opposing agents that work synergistically to maximize beneficial effects on sexual function while minimizing side effects. The company's lead compound, Lorexys, recently completed a Phase IIa clinical trial for the treatment of hypoactive sexual desire disorder (HSDD).

For more information please visit www.s1biopharma.com.

Contact:
Nick Sitchon
nsitchon@s1biopharma.com
212-895-8915


'/>"/>
SOURCE S1 Biopharma
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma
2. EMD Millipore Introduces Compaction Technology to Improve Solubility and Facilitate Handling of Cell Culture Media Used in Biopharmaceutical Production
3. Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting
4. PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference
5. Array BioPharma To Present At The Jefferies 2015 Global Healthcare Conference
6. Technical Coverage on Biotech Stocks -- Anthera Pharma, RXi Pharma, MiMedx, Sarepta Therapeutics, and Navidea Biopharma
7. Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named
8. DS Biopharma to Present at UBS Global Healthcare Conference
9. WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition
10. CTI BioPharma Reports First Quarter 2015 Financial Results
11. PDL BioPharma Announces First Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... August 07, 2018 , ... ... appointment of Richard A. Stark to assume the role of Sanarus Technologies President, effective immediately. ... years of strategic development, marketing and sales experience in medical device toward finding new ...
(Date:8/3/2018)... ... ... In order to improve safety for everyone throughout the summer, personal injury ... risks of injury that many amusement park rides present during the summer months. ... thrilling ride on a roller coaster. Unfortunately, these fun times can quickly turn dangerous ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... gummy smile for custom crown lengthening treatment at his Eden Prairie, ... line and an unsteady self-conscious. Using decades of experience, Dr. Sanchez is excited ...
Breaking Medicine Technology:
(Date:8/9/2018)... ... August 09, 2018 , ... ... engaged as an Operating Partner and will have an exclusive relationship with the ... in the firm’s strategic planning, human capital sourcing, and deal origination, evaluation and ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American Psychiatric ... to receive the 2018 Board of Directors Student Scholarship . The APNA ... psychiatric-mental health nursing and develop the next generation of leaders in the profession. ...
(Date:8/2/2018)... ... 2018 , ... Dr. Srini Pillay , best-selling author of TINKER ... could care less, demonstrating a “whatever” attitude toward life, people, and situations around them. ... often overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition occurs ...
(Date:8/2/2018)... ... August 02, 2018 , ... A ... of topics in acute pain management. In The Role of Acute Care in ... Prescribing Engagement Network—an innovative approach to the opioid epidemic launched in the state ...
(Date:8/2/2018)... ... August 02, 2018 , ... Tunstall Americas has launched their ... can partner with Tunstall Americas for After-hours call-handling, Overflow call-handling, and Appointment Scheduling ... expand their suite of Patient Access Solutions, and gives their existing and new ...
Breaking Medicine News(10 mins):